Advertisement

Topics

Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome

2010-07-15 17:00:00 | BioPortfolio

Summary

The purpose of this study is to exploratively investigate the clinical efficacy of rebamipide on dry mouth in patients with Sjögren’s syndrome in comparison with placebo.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Conditions

Xerostomia

Intervention

Rebamipide

Location

Otsuka Pharmaceutical Co., Ltd.
Tokyo
Japan

Status

Completed

Source

Otsuka Pharmaceutical Co., Ltd.

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [66 Associated Clinical Trials listed on BioPortfolio]

Study of Rebamipide Eye Drops to Treat Dry Eye

The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivi...

An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis

The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with act...

PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity

To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.

Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions

This clinical trial evaluated the gastroprotection obtained by the use of rebamipide 300 mg (2x daily) and rabeprazole 20 mg/day (1x daily) associated or not in the prevention of gastric l...

PubMed Articles [24 Associated PubMed Articles listed on BioPortfolio]

The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice.

The superoxide dismutase-1 knockout (Sod1-/-) mouse is an age-related dry eye mouse model. We evaluated the role of 2% rebamipide ophthalmic solution on the conjunctiva and ocular surface alterations ...

Predictive value of ultrasound scoring in relation to clinical and histological parameters in xerostomia patien.

Salivary gland dysfunction is one of the main clinical features of SS, manifested by xerostomia with subsequent complications and well-established effects on the person's quality of life.

Denture adhesives' effect on retention of prostheses in patients with xerostomia.

Patients with xerostomia have difficulties using dentures. Application of denture adhesives (DAs) can improve the stabilization of prostheses.

Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia.

Xerostomia following radioiodine therapy (RIT) in patients suffering from differentiated thyroid cancer is a common side effect in 2 % to 67 % of patients treated with radioiodine (I-131). In order to...

Hyperbaric oxygen treatment for the management of radiation-induced xerostomia.

Hyperbaric oxygen therapy (HBOT) is widely used for the treatment of the late effects of radiation therapy. We report a prospective observational cohort study of 51 patients designed to examine the ef...

Medical and Biotech [MESH] Definitions

Decreased salivary flow.

A solution used for irrigating the mouth in xerostomia and as a substitute for saliva.

Drying and inflammation of the conjunctiva as a result of insufficient lacrimal secretion. When found in association with XEROSTOMIA and polyarthritis, it is called SJOGREN'S SYNDROME.

Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.

More From BioPortfolio on "Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial